Pryor Cashman client Marina Biotech, Inc. (formerly MDRNA, Inc.; Nasdaq: MRNA), a leading RNAi-based drug discovery and development company, announced on July 22, 2010 the consummation of the acquisition of Cequent Pharmaceuticals, Inc. and its clinical program in Familial Adenomatous Polyposis.

Pryor Cashman acted as Marina Biotech's legal advisor in the transaction, with attorneys from the firm’s Banking, Corporate, Tax and ERISA Groups contributing their expertise. The Pryor Cashman team was composed of Partners Lawrence Remmel and Michael Dunworth, and associates Michael Campoli, Matthew Young and Cory Lamonica.